Senti Biosciences (SNTI) News Today $2.17 -0.11 (-4.61%) As of 12:43 PM Eastern This is a fair market value price provided by Polygon.io. Learn more. Add Compare Share Share Headlines Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrendsBuy This Stock SNTI Latest News All Sources Trusted Sources MarketBeat Benzinga Bloomberg GlobeNewswire GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha TalkMarkets The Street TipRanks The Wall Street Journal Wall Street Zen Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent June 2025 May 2025 April 2025 March 2025 February 2025 January 2025 December 2024 November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 July 2022 Time Period Senti Bio Granted U.S. FDA Orphan Drug Designation for Use of First-in-Class Off-the-Shelf Logic Gated Selective CD33 OR FLT3 NOT EMCN CAR NK Cell Therapy, SENTI-202 to Treat Acute Myeloid LeukemiaJune 18 at 7:00 AM | globenewswire.comChardan Capital Reaffirms Buy Rating for Senti Biosciences (NASDAQ:SNTI)June 14, 2025 | americanbankingnews.comChardan Capital Reaffirms "Buy" Rating for Senti Biosciences (NASDAQ:SNTI)Chardan Capital reiterated a "buy" rating and issued a $12.00 price objective on shares of Senti Biosciences in a report on Thursday.June 12, 2025 | marketbeat.comSenti Biosciences Announces New Employment Inducement GrantsJune 9, 2025 | globenewswire.comINVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Senti Biosciences, Inc. - SNTIJune 7, 2025 | prnewswire.comLaidlaw & Co. Initiates Coverage of Senti Biosciences (SNTI) with Buy RecommendationJune 7, 2025 | msn.comINVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Senti Biosciences, Inc. - SNTIJune 6, 2025 | globenewswire.comSenti Bio to Participate in a Virtual Fireside Chat Hosted by Chardan Capital Markets, LLCJune 6, 2025 | globenewswire.comSenti Biosciences (NASDAQ:SNTI) Coverage Initiated at LaidlawLaidlaw assumed coverage on shares of Senti Biosciences in a research report on Friday. They set a "buy" rating and a $5.00 price target on the stock.June 6, 2025 | marketbeat.comINVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Senti Biosciences, Inc. - SNTIJune 2, 2025 | globenewswire.comINVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Senti Biosciences, Inc. - SNTIJune 1, 2025 | prnewswire.comSenti Biosciences, Inc. (NASDAQ:SNTI) Short Interest UpdateSenti Biosciences, Inc. (NASDAQ:SNTI - Get Free Report) was the recipient of a significant drop in short interest in the month of May. As of May 15th, there was short interest totalling 155,600 shares, a drop of 38.1% from the April 30th total of 251,400 shares. Based on an average daily volume of 92,600 shares, the short-interest ratio is presently 1.7 days. Currently, 2.0% of the company's stock are short sold.June 1, 2025 | marketbeat.comSenti Biosciences (NASDAQ:SNTI) Stock Price Down 3% - Time to Sell?Senti Biosciences (NASDAQ:SNTI) Trading Down 3% - Time to Sell?May 30, 2025 | marketbeat.comSenti Biosciences Receives Additional $1 Million from CIRM to Support Clinical Development of SENTI-202 Cell TherapyMay 23, 2025 | nasdaq.comSenti Bio to Present at LIVE! with Webull Corporate Connect: Virtual Biotech Investment WebinarMay 22, 2025 | globenewswire.comSenti Bio Receives Additional $1.0 Million Tranche from California Institute for Regenerative Medicines (CIRM) Grant for Advancing Clinical Development of SENTI-202May 22, 2025 | globenewswire.comINVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Senti Biosciences, Inc. - SNTIMay 20, 2025 | prnewswire.comSNTI Investors Have Opportunity to Join Senti Biosciences, Inc. Fraud Investigation with the Schall Law FirmMay 20, 2025 | prnewswire.comSNTI Investors Have Opportunity to Join Senti Biosciences, Inc. Fraud Investigation with the Schall Law FirmMay 15, 2025 | businesswire.comINVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Senti Biosciences, Inc. - SNTIMay 13, 2025 | globenewswire.comINVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Senti Biosciences, Inc. - SNTIMay 12, 2025 | prnewswire.comINVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Senti Biosciences, Inc. - SNTIMay 9, 2025 | globenewswire.comSenti Bio Releases Mechanism of Action Video for First-in-Class Off-the-Shelf Logic Gated Selective CD33 OR FLT3 NOT EMCN CAR NK Cell Therapy, SENTI-202May 8, 2025 | globenewswire.comSenti Bio Reports First Quarter 2025 Financial Results and Provides a Corporate Update on Positive SENTI-202 Clinical DevelopmentMay 6, 2025 | globenewswire.comINVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Senti Biosciences, Inc. - SNTIMay 6, 2025 | prnewswire.comSenti Biosciences (SNTI) to Release Earnings on ThursdaySenti Biosciences (NASDAQ:SNTI) will be releasing earnings before the market opens on Thursday, May 8. (View Earnings Report at https://www.marketbeat.com/earnings/reports/2025-5-8-senti-biosciences-inc-stock/)May 5, 2025 | marketbeat.comINVESTOR ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of Senti Biosciences, Inc. – SNTIMay 5, 2025 | globenewswire.comSenti Biosciences (NASDAQ:SNTI) Receives Buy Rating from Chardan CapitalChardan Capital reaffirmed a "buy" rating and set a $12.00 price target on shares of Senti Biosciences in a report on Friday.May 4, 2025 | marketbeat.comSenti Biosciences Announces Positive Data for SENTI-202 in Phase 1 Trial at AACR Annual Meeting 2025May 3, 2025 | nasdaq.comSenti Bio Releases Virtual Investor "What This Means" SegmentMay 3, 2025 | tmcnet.comSenti Bio Releases Virtual Investor “What This Means” SegmentMay 1, 2025 | globenewswire.comSenti Bio to Present at the Citizens JMP Life Sciences ConferenceApril 30, 2025 | globenewswire.comSenti Bio’s SENTI-202, a First-in-Class Off-the-Shelf Logic Gated Selective CD33 OR FLT3 NOT EMCN CAR NK Cell Therapy, Demonstrates Positive Preliminary Clinical Results in ...April 29, 2025 | seekingalpha.comINVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Senti Biosciences, Inc. - SNTIApril 29, 2025 | globenewswire.comSenti Bio's SENTI-202, a First-in-Class Off-the-Shelf Logic Gated Selective CD33 OR FLT3 NOT EMCN CAR NK Cell Therapy, Demonstrates Positive Preliminary Clinical Results in the Treatment of Patients with Relapsed/Refractory AMLApril 28, 2025 | globenewswire.comSenti Bio to hold a conference callApril 28, 2025 | markets.businessinsider.comSenti Biosciences to Host Conference Call on SENTI-202 Phase 1 Clinical Data Ahead of AACR Annual MeetingApril 26, 2025 | nasdaq.comSenti Bio to Host Conference Call and Webcast to Discuss SENTI-202 Clinical Data Being Presented at the American Association for Cancer Research (AACR) Annual Meeting 2025 on Monday, April 28th at 8:30 AM ETApril 24, 2025 | globenewswire.comSenti Bio Participates in a Virtual Investor KOL Connect SegmentApril 21, 2025 | globenewswire.comSenti Bio (NASDAQ: SNTI) to Participate in a Live Virtual Investor Closing Bell SegmentApril 16, 2025 | globenewswire.comSenti Bio appoints James Trager to Scientific Advisory BoardApril 11, 2025 | markets.businessinsider.comSenti Bio Bolsters Scientific Advisory Board with Appointment of James B. Trager, Ph.D.April 10, 2025 | globenewswire.comSenti Bio Bolsters Scientific Advisory Board with Appointment of James B. Trager, Ph.D.April 10, 2025 | globenewswire.comSenti Biosciences joins Webull’s Corporate Connect ServiceApril 9, 2025 | uk.investing.comSenti Bio Joins Webull Corporate Connect Service PlatformApril 7, 2025 | globenewswire.comSenti Bio to Showcase SENTI-202 Clinical Data and Novel Logic Gated Gene Circuit Mechanism of Action in Oral and Poster Presentations at the American Association for Cancer Research (AACR) Annual Meeting 2025April 3, 2025 | globenewswire.comSenti Bio files $300M mixed securities shelfMarch 21, 2025 | markets.businessinsider.comSenti Bio files to sell 52.9M shares of common stock for holdersMarch 21, 2025 | markets.businessinsider.comSenti Biosciences, Inc.: Senti Bio Announces Fourth Quarter and Full Year 2024 Financial Results and Recent Pipeline and Corporate HighlightsMarch 21, 2025 | finanznachrichten.deSenti Bio reports Q4 EPS (67c), consensus ($3.13)March 21, 2025 | markets.businessinsider.com Get Senti Biosciences News Delivered to You Automatically Sign up to receive the latest news and ratings for SNTI and its competitors with MarketBeat's FREE daily newsletter. Email Address SNTI Media Mentions By Week SNTI Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. SNTI News Sentiment▼0.670.68▲Average Medical News Sentiment SNTI News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. SNTI Articles This Week▼21▲SNTI Articles Average Week Get Senti Biosciences News Delivered to You Automatically Sign up to receive the latest news and ratings for SNTI and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies Monte Rosa Therapeutics News Alpha Teknova News Gossamer Bio News Corvus Pharmaceuticals News ProKidney News Amarin News Olema Pharmaceuticals News Cidara Therapeutics News Entrada Therapeutics News Atea Pharmaceuticals News Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:SNTI) was last updated on 6/20/2025 by MarketBeat.com Staff From Our PartnersPresidential Bombshell: $150T Resource to Be Released as soon as this Summer?Something extraordinary is happening in Washington. For the first time in over a century, a sitting Preside...Paradigm Press | Sponsored379 passengers walked away from thisWhy Elon Musk Just Invested $51 Million Into Brand New “Miracle Metal” Developed by MIT ScientistsTrue Market Insiders | SponsoredWhat a “Mar-a-Lago Accord” could mean for the US dollar.25-Year Market Vet Issues Urgent Dollar Warning He's spent 25 years tracking the flow of global money - now...Stansberry Research | SponsoredThe Robotics Revolution has arrived … and one $7 stock could take off as a result.Something big is brewing in Washington. According to my research, an executive order from President Trump c...Weiss Ratings | SponsoredTrump’s true trade war strategyThe media and financial pundits are all misreading Trump’s actions. They think Trump wants to make Canada t...Porter & Company | SponsoredTrump Makes Major Crypto AnnouncementTrump's crypto revolution is now fully underway and now, we believe he’s about to deliver on his biggest promi...Crypto 101 Media | SponsoredMost Bitcoin holders have no idea this existsHere’s what 99% of Bitcoin holders don’t know: There’s a way to amplify your Bitcoin gains without buying m...Brownstone Research | SponsoredGold Just Jumped Again. Here’s How to Get PaidGold prices just spiked again. As I write this, gold is trading near $3,400 an ounce. But here's the thi...Investors Alley | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Senti Biosciences, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Senti Biosciences With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Buy SNTI Stock Free SNTI Stock Alerts